27 research outputs found
Recommended from our members
Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: Involvement of retrograde and anterograde axonal propagation.
In Parkinson's disease, some of the first alpha-synuclein aggregates appear in the olfactory system and the dorsal motor nucleus of the vagus nerve before spreading to connected brain regions. We previously demonstrated that injection of alpha-synuclein fibrils unilaterally into the olfactory bulb of wild type mice leads to widespread synucleinopathy in brain regions directly and indirectly connected to the injection site, consistently, over the course of periods longer than 6 months. Our previously reported observations support the idea that alpha-synuclein inclusions propagates between brain region through neuronal networks. In the present study, we further defined the pattern of propagation of alpha-synuclein inclusions and developed a mathematical model based on known mouse brain connectivity. Using this model, we first predicted the pattern of alpha-synuclein inclusions propagation following an injection of fibrils into the olfactory bulb. We then analyzed the fitting of these predictions to our published histological data. Our results demonstrate that the pattern of propagation we observed in vivo is consistent with axonal transport of alpha-synuclein aggregate seeds, followed by transsynaptic transmission. By contrast, simple diffusion of alpha-synuclein fits very poorly our in vivo data. We also found that the spread of alpha-synuclein inclusions appeared to primarily follow neural connections retrogradely until 9 months after injection into the olfactory bulb. Thereafter, the pattern of spreading was consistent with anterograde propagation mathematical models. Finally, we applied our mathematical model to a different, previously published, dataset involving alpha-synuclein fibril injections into the striatum, instead of the olfactory bulb. We found that the mathematical model accurately predicts the reported progressive increase in alpha-synuclein neuropathology also in that paradigm. In conclusion, our findings support that the progressive spread of alpha-synuclein inclusions after injection of protein fibrils follows neural networks in the mouse connectome
The role of Galectin-3 in α-synuclein-induced microglial activation
Background:
Parkinson
’
s disease (PD) is the most prevalent neurodegenerative motor disorder. The neuropathology is
characterized by intraneuronal protein aggregates of
α
-synuclein and progressive degeneration of dopaminergic
neurons within the substantia nigra. Previous studies have shown that extracellular
α
-synuclein aggregates can activate
microglial cells, induce inflammation and contribute to the neurodegenerative process in PD. However, the signaling
pathways involved in
α
-synuclein-mediated microglia activation are poorly understood. Galectin-3 is a member of a
carbohydrate-binding protein family involved in cell activation and inflammation. Therefore, we investigated whether
galectin-3 is involved in the microglia activation triggered by
α
-synuclein.
Results:
We cultured microglial (BV2) cells and induced cell activation by addition of exogenous
α
-synuclein monomers
or aggregates to the cell culture medium. This treatment induced a significant increase in the levels of proinflammatory
mediators including the inducible Nitric Oxide Synthase (iNOS), interleukin 1 Beta (IL-1
β
) and Interleukin-12 (IL-12). We
then reduced the levels of galectin-3 expression using siRNA or pharmacologically targeting galectin-3 activity using
bis-(3-deoxy-3-(3-fluorophenyl-1
H
-1,2,3-triazol-1-yl)-
β
-D-galactopyranosyl)-sulfane. Both approaches led to a significant
reduction in the observed inflammatory response induced by
α
-synuclein. We confirmed these findings using primary
microglial cells obtained from wild-type and galectin-3 null mutant mice. Finally, we performed injections of
α
-synuclein in the olfactory bulb of wild type mice and observed that some of the
α
-synuclein was taken up by
activated microglia that were immunopositive for galectin-3.
Conclusions:
We show that
α
-synuclein aggregates induce microglial activation and demonstrate for the first time that
galectin-3 plays a significant role in microglia activation induced by
α
-synuclein. These results suggest that genetic
down-regulation or pharmacological inhibition of galectin-3 might constitute a novel therapeutic target in PD and
other synucleinopathie
Loss of One Engrailed1 Allele Enhances Induced α-Synucleinopathy
Parkinson’s disease (PD) is a synucleinopathy that has multiple neuropathological characteristics, with nigrostriatal dopamine system degeneration being a core feature. Current models of PD pathology typically fail to recapitulate several attributes of the pathogenic process and neuropathology. We aimed to define the effects of combining a mouse model exhibiting multiple PD-like changes with intrastriatal injections of α-synuclein (α-syn) pre-formed fibril (PFFs) aggregates. We employed the heterozygous Engrailed 1 (En1+/–) mouse that features several pathophysiological hallmarks of clinical PD.La enfermedad de Parkinson (EP) es una sinucleinopatía que tiene múltiples características neuropatológicas, siendo la degeneración del sistema dopaminérgico nigroestriatal una característica central. Los modelos actuales de patología de la EP generalmente no logran recapitular varios atributos del proceso patogénico y la neuropatología. Nuestro objetivo fue definir los efectos de combinar un modelo de ratón que presentaba múltiples cambios similares a los de la EP con inyecciones intraestriatales de agregados de fibrillas preformadas (PFF) de α-sinucleína (α-syn). Empleamos el ratón heterocigoto Engrailed 1 (En1+/–) que presenta varias características fisiopatológicas de la EP clínica
Olfactory aging in normal mice and in an Alzheimer disease model : implication of neurogenesis and noradrenergic system
Au cours du vieillissement normal et du vieillissement pathologique de type Alzheimer, des altérations olfactives surviennent. Très précoces dans la maladie d'Alzheimer, ces troubles pourraient être signe du développement de la maladie, bien avant l'apparition des signes de déclin cognitif. Il nous paraissait donc important de caractériser et de différencier de manière précise les troubles olfactifs associés au vieillissement normal de ceux associés au vieillissement pathologique et leurs corrélats cellulaires. Notre première étude a pour objectif de clarifier le vieillissement de la fonction olfactive et sa plasticité chez le rongeur. Dans ce travail, le vieillissement apparaît comme un processus complexe, qui n'est pas une simple dégradation générale de la fonction olfactive, mais un processus qui touche de manière hétérogène les différents aspects de la perception olfactive, et dont le signe le plus marquant semble être la perte de plasticité des performances olfactives, de la neurogenèse et du système noradrénergique en réponse à une stimulation. Nous montrons que la mémoire olfactive et sa modulation par l'enrichissement de l'environnement olfactif est plus sensible au vieillissement normal que la discrimination olfactive. Le fonctionnement basal (discrimination facile et mémoire à très court terme) persiste, bien que la neurogenèse soit altérée de manière drastique et cela malgré le rôle majeur des néo neurones pour la fonction olfactive chez l'animal jeune. Nos données mettent également en évidence une altération biphasique de la neurogenèse (réduction de prolifération, puis chez les animaux sénescents, une altération de la différenciation et de la survie des néo-neurones), et une réponse plastique du système noradrénergique qui persiste à âge moyen, alors que la neurogenèse ne réponds déjà plus à l'enrichissement olfactif. Ce travail apporte ainsi les bases nécessaires pour une comparaison des altérations olfactives liées à l'âge avec celles présentes dans la MA. Notre seconde étude nous a permis de confirmer l'existence de déficits olfactifs précoces chez le modèle murin APP/PS1 de maladie d'Alzheimer, ainsi que l'implication du système noradrénergique dans ces altérations. Induite par un traitement chronique au DSP4, la déplétion noradrénergique aggrave le phénotype amyloïde dans le BO, et accentue sévèrement les troubles olfactifs. Ces données contribuent à valider l'utilisation de modèle olfactif pour l'étude des altérations précoces observées dans la maladie d'Alzheimer, en combinant la déplétion noradrénergique pour modéliser les altérations observées dans la maladie humaine, et étudier les mécanismes physiopathologiques survenant dans la MA.During normal aging and pathological aging like Alzheimer's disease appear olfactory deficits. These deficits occur very early in Alzheimer's disease and could be among the first signs of the disease. Thus, the definition, comparison of olfactory trouble appearing in normal aging versus Alzheimer's disease and their cellular correlates is a crucial step toward comprehension of the disease. The first study was aimed at clarifying olfactory function in aging and it's plasticity in normal mice. Aging appears as a very complex process, touching heterogenatly olfactory components. The major sign of aging is the lack of plasticity of olfactory performances, neurogenic processes and noradrenergic system in response to an olfactory enrichment. Our datas show that olfactory memory and it's modulation by olfactory enrichment is more sensible to aging than olfactory discrimination. Despite the strong impairment of neurogenesis in aging, and regardless to it's major role in olfactory processes in young animals, basal olfactory performances (easy discrimination and very short term memory) remains intact in aged animals. We also show that olfactory neurogenesis is impaired in a biphasic way during aging (first, reduction of proliferation, and then in senescent mice, impairment of differentiation and survival in the olfactory bulb). Noradrenergic system plasticity persists in middle aged animals, contrarily to neurogenesis which does not respond to olfactory enrichment. Thus, this work gives us the background necessary to compare olfactory deficits in normal and pathological aging. Our second study confirms that olfactory troubles occurs early in APP/PS1 mice, our Alzheimer's disease model, and confirms the implication of noradrenergic deficits. A chronic depletion in noradrenalin produced by treatments with DSP4 aggravates amyloïd deposition and olfactory deficits in our mice. These datas provide a strong support to the use of olfactory modality to study early signs of the disease, and to combine noradrenergic depletion to reproduce clinical and physiopatholocical signs of Alzheimer's disease in human
Vieillissement olfactif chez la souris normale et chez la souris APP/PS1, modèle de la maladie d'Alzheimer : implications de la neurogenèse et du système noradrénergique
During normal aging and pathological aging like Alzheimer's disease appear olfactory deficits. These deficits occur very early in Alzheimer's disease and could be among the first signs of the disease. Thus, the definition, comparison of olfactory trouble appearing in normal aging versus Alzheimer's disease and their cellular correlates is a crucial step toward comprehension of the disease. The first study was aimed at clarifying olfactory function in aging and it's plasticity in normal mice. Aging appears as a very complex process, touching heterogenatly olfactory components. The major sign of aging is the lack of plasticity of olfactory performances, neurogenic processes and noradrenergic system in response to an olfactory enrichment. Our datas show that olfactory memory and it's modulation by olfactory enrichment is more sensible to aging than olfactory discrimination. Despite the strong impairment of neurogenesis in aging, and regardless to it's major role in olfactory processes in young animals, basal olfactory performances (easy discrimination and very short term memory) remains intact in aged animals. We also show that olfactory neurogenesis is impaired in a biphasic way during aging (first, reduction of proliferation, and then in senescent mice, impairment of differentiation and survival in the olfactory bulb). Noradrenergic system plasticity persists in middle aged animals, contrarily to neurogenesis which does not respond to olfactory enrichment. Thus, this work gives us the background necessary to compare olfactory deficits in normal and pathological aging. Our second study confirms that olfactory troubles occurs early in APP/PS1 mice, our Alzheimer's disease model, and confirms the implication of noradrenergic deficits. A chronic depletion in noradrenalin produced by treatments with DSP4 aggravates amyloïd deposition and olfactory deficits in our mice. These datas provide a strong support to the use of olfactory modality to study early signs of the disease, and to combine noradrenergic depletion to reproduce clinical and physiopatholocical signs of Alzheimer's disease in human.Au cours du vieillissement normal et du vieillissement pathologique de type Alzheimer, des altérations olfactives surviennent. Très précoces dans la maladie d'Alzheimer, ces troubles pourraient être signe du développement de la maladie, bien avant l'apparition des signes de déclin cognitif. Il nous paraissait donc important de caractériser et de différencier de manière précise les troubles olfactifs associés au vieillissement normal de ceux associés au vieillissement pathologique et leurs corrélats cellulaires. Notre première étude a pour objectif de clarifier le vieillissement de la fonction olfactive et sa plasticité chez le rongeur. Dans ce travail, le vieillissement apparaît comme un processus complexe, qui n'est pas une simple dégradation générale de la fonction olfactive, mais un processus qui touche de manière hétérogène les différents aspects de la perception olfactive, et dont le signe le plus marquant semble être la perte de plasticité des performances olfactives, de la neurogenèse et du système noradrénergique en réponse à une stimulation. Nous montrons que la mémoire olfactive et sa modulation par l'enrichissement de l'environnement olfactif est plus sensible au vieillissement normal que la discrimination olfactive. Le fonctionnement basal (discrimination facile et mémoire à très court terme) persiste, bien que la neurogenèse soit altérée de manière drastique et cela malgré le rôle majeur des néo neurones pour la fonction olfactive chez l'animal jeune. Nos données mettent également en évidence une altération biphasique de la neurogenèse (réduction de prolifération, puis chez les animaux sénescents, une altération de la différenciation et de la survie des néo-neurones), et une réponse plastique du système noradrénergique qui persiste à âge moyen, alors que la neurogenèse ne réponds déjà plus à l'enrichissement olfactif. Ce travail apporte ainsi les bases nécessaires pour une comparaison des altérations olfactives liées à l'âge avec celles présentes dans la MA. Notre seconde étude nous a permis de confirmer l'existence de déficits olfactifs précoces chez le modèle murin APP/PS1 de maladie d'Alzheimer, ainsi que l'implication du système noradrénergique dans ces altérations. Induite par un traitement chronique au DSP4, la déplétion noradrénergique aggrave le phénotype amyloïde dans le BO, et accentue sévèrement les troubles olfactifs. Ces données contribuent à valider l'utilisation de modèle olfactif pour l'étude des altérations précoces observées dans la maladie d'Alzheimer, en combinant la déplétion noradrénergique pour modéliser les altérations observées dans la maladie humaine, et étudier les mécanismes physiopathologiques survenant dans la MA
Alpha-synuclein aggregation and propagation in synucleinopathies; influence of the structure of aggregates
International audienc
α-Synuclein: The Long Distance Runner.
Parkinson's disease is characterized by α-synuclein pathology in the form of Lewy bodies and Lewy neurites. Braak et al described the spatial and temporal spread of α-synuclein pathology in Parkinson's disease. Recent experimental studies have demonstrated that α-synuclein can transfer from cell to cell. In this review, we highlight the involvement of α-synuclein in Parkinson's disease and in Braak's staging of Parkinson's disease pathology. We discuss whether a prion-like mechanism of α-synuclein spread might contribute to Parkinson's disease pathology. We describe recent studies investigating cell-to-cell transfer of α-synuclein and focus our review on the long-distance axonal transport of α-synuclein along neurons
Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice.
α-Synuclein (α-syn) is a protein prevalent in neural tissue and known to undergo axonal transport. Intracellular α-syn aggregates are a hallmark of Parkinson's disease (PD). Braak and collaborators have suggested that in people who are destined to eventually develop PD, α-syn aggregate pathology progresses following a stereotypic pattern, starting in the olfactory bulb (OB) and the gut. α-Synuclein aggregates are postulated to spread to interconnected brain regions over several years. Thus, propagation of the pathology via neural pathways can potentially explain how α-syn aggregates spread in PD. We have now studied if α-syn can transfer from the OB to other brain structures through neural connections, by injecting different molecular species of human α-syn (monomers, oligomers, fibrils) into the OB of wild-type mice. We found that non-fibrillar human α-syn is taken up very quickly by OB neurons. Within minutes to hours, it is also found in neurons in structures connected to the OB. Conversely, when we injected bovine serum albumin used as a control protein, we found that it does not diffuse beyond the OB, is rarely taken up by OB cells, and does not transfer to other structures. Taken together, our results show that OB cells readily take up α-syn, and that monomeric and oligomeric, but not fibrillar, forms of α-syn are rapidly transferred to interconnected structures within the timeframe we explored. Our results support the idea that α-syn can transfer along neural pathways and thereby contribute to the progression of the α-syn-related pathology
Newborn Neurons in the Olfactory Bulb Selected for Long-Term Survival through Olfactory Learning Are Prematurely Suppressed When the Olfactory Memory Is Erased
International audienceA role for newborn neurons in olfactory memory has been proposed based on learning-dependent modulation of olfactory bulb neuro-genesis in adults. We hypothesized that if newborn neurons support memory, then they should be suppressed by memory erasure. Using an ecological approach in mice, we showed that behaviorally breaking a previously learned odor-reward association prematurely suppressed newborn neurons selected to survive during initial learning. Furthermore, intrabulbar infusions of the caspase pan-inhibitor ZVAD (benzyloxycarbonyl-Val-Ala-Asp) during the behavioral odor-reward extinction prevented newborn neurons death and erasure of the odor-reward association. Newborn neurons thus contribute to the bulbar network plasticity underlying long-term memory